Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, is a barrier in the treatment of TB. Globally, approximately 3.4% of new TB patients and 20% of the patients with a history of previous treatment for TB were diagnosed with MDR-TB. The treatment of MDR-TB requires medications for a long duration (up to 20–24 months) with less effective and toxic second-line drugs and has unfavorable outcomes. However, treatment outcomes are expected to improve due to the introduction of a new agent (bedaquiline), repurposed drugs (linezolid, clofazimine, and cycloserine), and technological advancement in rapid drug sensitivity testing. The World Health Organization (WHO) released a rapid communication in 2018, followed by consolidated guidelines for the treatment of MDR-TB in 2019 based on clinical trials and an individual patient data meta-analysis. In these guidelines, the WHO suggested reclassification of second-line anti-TB drugs and recommended oral treatment regimens that included the new and repurposed agents. The aims of this article are to review the treatment strategies of MDR-TB based on the 2019 WHO guidelines regarding the management of MDR-TB and the diagnostic techniques for detecting resistance, including phenotypic and molecular drug sensitivity tests.
Citations
Citations to this article as recorded by
Computational insights into potential marine natural products as selective inhibitors of Mycobacterium tuberculosis InhA: A structure-based virtual screening study Manikandan Jayaraman, Vijayakumar Gosu, Rajalakshmi Kumar, Jeyakanthan Jeyaraman Computational Biology and Chemistry.2024; 108: 107991. CrossRef
Targeting of essential mycobacterial replication enzyme DnaG primase revealed Mitoxantrone and Vapreotide as novel mycobacterial growth inhibitors** Waseem Ali, Salma Jamal, Rishabh Gangwar, Faraz Ahmed, Rahul Sharma, Meetu Agarwal, Javaid Ahmad Sheikh, Abhinav Grover, Sonam Grover Molecular Informatics.2024;[Epub] CrossRef
A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT) Ashwin Karnan, Ulhas Jadhav, Babaji Ghewade, Anjana Ledwani, Poorna Shivashankar Cureus.2024;[Epub] CrossRef
Design, synthesis and biological evaluation of novel pyrido-[2,3-d]-pyrimidin-2-amine analogues as antimycobacterial agents Boddupalli Venkata Siva Kumar, Yogesh Mahadu Khetmalis, Kosana Sai Chaitanya, Ala Chandu, Gauri Shetye, Rui Ma, Sankaranarayanan Murugesan, Scott G. Franzblau, Kondapalli Venkata Gowri Chandra Sekhar Journal of Molecular Structure.2024; 1303: 137600. CrossRef
Direct TAMRA-dUTP labeling of M. tuberculosis genes using loop-mediated isothermal amplification (LAMP) Basma Altattan, Jasmin Ullrich, Emily Mattig, Aline Poppe, Renata Martins, Frank F. Bier Scientific Reports.2024;[Epub] CrossRef
Antimicrobial peptides as new-generation antibiotics against Mycobacterium Parisa Eslami, Adnan Khosravi Journal of Preventive, Diagnostic and Treatment Strategies in Medicine.2024; 3(1): 6. CrossRef
A Case of Multidrug-Resistant Tuberculosis in an Active Duty Military Health Care Worker Amanda E Saunders, Kevin M Shanahan, John W Downs Military Medicine.2024;[Epub] CrossRef
Factors Associated with Non-Adherence to Treatment Among Migrants with MDR-TB in Wuhan, China: A Cross-Sectional Study Kunhe Lin, Li Xiang Risk Management and Healthcare Policy.2024; Volume 17: 727. CrossRef
Development of a self-microemulsifying drug delivery system to deliver delamanid via a pressurized metered dose inhaler for treatment of multi-drug resistant pulmonary tuberculosis Himanshu Paliwal, Titpawan Nakpheng, Pijush Kumar Paul, K. Prem Ananth, Teerapol Srichana International Journal of Pharmaceutics.2024; 655: 124031. CrossRef
Drug Targets, Current and Future Therapeutics for the Treatment of
Multi Drug Resistant Tuberculosis with their Clinical Applications: A
Critical Review Deepshikha Singh, Vikram Singh, Subhankar P. Mandal, Karen Dsouza, B.R. Prashantha Kumar, Sheshagiri R. Dixit Current Drug Therapy.2024; 19(3): 317. CrossRef
Synthesis and Structure–Activity Relationship of 2,6-Disubstituted Thiosemicarbazone Derivatives of Pyridine as Potential Antituberculosis Agents Dagmara Ziembicka, Katarzyna Gobis, Małgorzata Szczesio, Andrzej Olczak, Ewa Augustynowicz-Kopeć, Agnieszka Głogowska, Izabela Korona-Głowniak, Krzysztof Bojanowski Materials.2023; 16(1): 448. CrossRef
Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now Kona Chowdhury, Rahnuma Ahmad, Susmita Sinha, Siddhartha Dutta, Mainul Haque Cureus.2023;[Epub] CrossRef
Anxiety and depression level of patients with multidrug-resistant tuberculosis (MDR-TB) in two hospitals in Banten province, Indonesia Tirta Darmawan Susanto, Allen Widysanto, Darien Alfa Cipta, Arron Tanara, Ghivarell Rizkie Wirawan, Adeline Bercadina Kosim, Christabella Maria Djoni, Ervinna Tantri, Chandni Kumar, Chelsie Angelius Dialogues in Health.2023; 2: 100115. CrossRef
Characteristics of Previous Tuberculosis Treatment History in Patients with Treatment Failure and the Impact on Acquired Drug-Resistant Tuberculosis Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Wiwik Kurnia Ilahi, Amelia Tantri Anggraeni Antibiotics.2023; 12(3): 598. CrossRef
Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics Srestha Mukherjee, Summaya Perveen, Anjali Negi, Rashmi Sharma Tuberculosis.2023; 140: 102340. CrossRef
Assessment of the Diagnostic Utility of GeneXpert Mycobacterium tuberculosis/Rifampicin (MTB/RIF) Assay in the Suspected Cases of Tuberculous Meningitis Sakshi Patel, Malti Dadheech, Anand K Maurya, Jitendra Singh, Shashank Purwar, Nirendra Rai, Radha Sarawagi, Ankur Joshi, Sagar Khadanga Cureus.2023;[Epub] CrossRef
Tandem LC-MS Identification of Antitubercular Compounds in Zones of Growth Inhibition Produced by South African Filamentous Actinobacteria Daniel J. Watson, Lubbe Wiesner, Tlhalefo Matimela, Denzil Beukes, Paul R. Meyers Molecules.2023; 28(11): 4276. CrossRef
Drug-Resistant Tuberculosis Stigma Among HealthCare Workers Toward the Development of a Stigma-Reduction Strategy: A Scoping Review Lolita Liboon Aranas, Khorshed Alam, Prajwal Gyawali, Rashidul Mahumud Alam INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2023;[Epub] CrossRef
Quality Mindset: The Missing Ingredient in Tuberculosis Care and Control in Togo Kossivi Agbélénko Afanvi, Mohammed Fall Dogo, Koffi Atsu Aziagbé, Komi Séraphin Adjoh, Koumavi Kristoli Didier Ekouévi European Journal of Theoretical and Applied Sciences.2023; 1(4): 36. CrossRef
Machine Learning of the Whole Genome Sequence of Mycobacterium tuberculosis: A Scoping PRISMA-Based Review Ricardo Perea-Jacobo, Guillermo René Paredes-Gutiérrez, Miguel Ángel Guerrero-Chevannier, Dora-Luz Flores, Raquel Muñiz-Salazar Microorganisms.2023; 11(8): 1872. CrossRef
Cotreatment With Clofazimine and Rapamycin Eliminates Drug-Resistant Tuberculosis by Inducing Polyfunctional Central Memory T-Cell Responses Dhiraj Kumar Singh, Ashima Bhaskar, Isha Pahuja, Aishwarya Shaji, Barnani Moitra, Yufang Shi, Ved Prakash Dwivedi, Gobardhan Das The Journal of Infectious Diseases.2023; 228(9): 1166. CrossRef
Treatment of drug-resistant tuberculosis in children and young adolescents in Brazil Fernanda Bruzadelli Paulino da Costa, Thaís Zamboni Berra, Jaqueline Garcia de Almeida Ballestero, Patricia Bartholomay Oliveira, Daniele Maria Pelissari, Yan Mathias Alves, Antônio Carlos Vieira Ramos, Juliana Queiroz Rocha de Paiva, Titilade Kehinde Aya Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2023; 33: 100388. CrossRef
Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen Mycobacterium tuberculosis Giuseppe Mancuso, Angelina Midiri, Silvia De Gaetano, Elena Ponzo, Carmelo Biondo Microorganisms.2023; 11(9): 2277. CrossRef
Drug-resistant Monoarticular Wrist Joint Tuberculosis in Renal Transplant Recipient with Literature Review Jasmine Sethi, Vignesh Subramani, Rajender Kumar, Shivakumar Patil, Ashish Sharma Indian Journal of Transplantation.2023; 17(3): 371. CrossRef
Predictive capabilities of baseline radiological findings for early and late disease outcomes within sensitive and multi-drug resistant tuberculosis cases Gabriel Rosenfeld, Andrei Gabrielian, Darrell Hurt, Alex Rosenthal European Journal of Radiology Open.2023; 11: 100518. CrossRef
Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies Mahesh Kumar, Tarun Virmani, Girish Kumar, Rohitas Deshmukh, Ashwani Sharma, Sofia Duarte, Pedro Brandão, Pedro Fonte Pharmaceuticals.2023; 16(10): 1360. CrossRef
A systematic review and meta-analysis on the correlation between HIV infection and multidrug-resistance tuberculosis Yulong Song, Qian Jin, Jihai Qiu, Dan Ye Heliyon.2023; 9(11): e21956. CrossRef
Current Insights into Diagnosing and Treating Neurotuberculosis in Adults Sofiati Dian, Ahmad Rizal Ganiem, Lindsey HM te Brake, Arjan van Laarhoven CNS Drugs.2023; 37(11): 957. CrossRef
Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis Temesgen Yihunie Akalu, Archie C. A. Clements, Haileab Fekadu Wolde, Kefyalew Addis Alene Scientific Reports.2023;[Epub] CrossRef
Multi-Drug Resistance Tuberculosis (MDR-TB) Challenges in India: A Review Deepak Vishwakarma, Abhay Gaidhane, Sweta Sahu, Ashwini S Rathod Cureus.2023;[Epub] CrossRef
Multidrug-resistant Tuberculosis and its Implication with COVID-19 Jasmine Arya, Sweety Dahiya, Anil Kumar Chhillar Coronaviruses.2023;[Epub] CrossRef
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance Summaya Perveen, Diksha Kumari, Kuljit Singh, Rashmi Sharma European Journal of Medicinal Chemistry.2022; 229: 114066. CrossRef
Abdominal Tuberculosis Mimicking Ovarian Cancer: A Case Report and Review of the Literature Ikhwan Rinaldi, Abdul Muthalib, Djaja Gosal, Teguh Wijayadi, Barlian Sutedja, Tjondro Setiawan, Andika Gunawan, Nelly Susanto, Lingga Magdalena, Diah Rini Handjari, Fetisari Kurniawan, Aisyah Rifani, Kevin Winston International Medical Case Reports Journal.2022; Volume 15: 169. CrossRef
Pediatric Tuberculosis Management: A Global Challenge or Breakthrough? Lehlogonolo N. F. Maphalle, Bozena B. Michniak-Kohn, Modupe O. Ogunrombi, Oluwatoyin A. Adeleke Children.2022; 9(8): 1120. CrossRef
Various approaches to improving adherence of patients with tuberculosis. Prospects for the use of additive technologies in TB practice A. G. Naumov, A. S. Shprykov PULMONOLOGIYA.2022; 34(1): 80. CrossRef
Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review Gabriel S. Oliveira, Raquel P. Costa, Paula Gomes, Maria Salomé Gomes, Tânia Silva, Cátia Teixeira Pharmaceuticals.2021; 14(4): 323. CrossRef
Treatment of Human Babesiosis: Then and Now Isaline Renard, Choukri Ben Mamoun Pathogens.2021; 10(9): 1120. CrossRef
Novel mutations detected from drug resistant Mycobacterium tuberculosis isolated from North East of Thailand Ei Phoo Thwe, Wises Namwat, Porntip Pinlaor, Kulrattana Rueangsak, Arunnee Sangka World Journal of Microbiology and Biotechnology.2021;[Epub] CrossRef
On the Mechanism of Development of Autoimmune Diseases Following Exposure to Inactivated Mycobacterium tuberculosis SV Skupnevskiy, GM Trukhina, EG Pukhaeva, AK Badtiev, FK Rurua, FE Batagova, ZhG Farnieva ЗДОРОВЬЕ НАСЕЛЕНИЯ И СРЕДА ОБИТАНИЯ - ЗНиСО / PUBLIC HEALTH AND LIFE ENVIRONMENT.2021; : 76. CrossRef
Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment Suman Saurabh, Pankaj Bhardwaj Journal of Family Medicine and Primary Care.2021; 10(12): 4607. CrossRef
Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis Ionela-Alina Grosu-Creangă, Antigona Carmen Trofor, Radu Adrian Crișan-Dabija, Daniela Robu-Popa, Cristina Mihaela Ghiciuc, Elena Cătălina Lupușoru Pneumologia.2021; 70(3): 117. CrossRef
Advances in the science and treatment of respiratory diseases Jin Hong Chung Yeungnam University Journal of Medicine.2020; 37(4): 251. CrossRef
BACKGROUND Recent studies have shown that the nontuberculosis mycobacterium (NTM) recovery rate in clinical cultures has increased within Korea. However, another study conducted by a secondary hospital within Daegu reported different results. Therefore, the purpose of this study is to understand and evaluate the microbiological distribution and clinical features of NTM in Daegu. METHODS: A retrospective study was conducted on 11,672 respiratory specimens undergoing acid fast bacilli (AFB) culture from 6,685 subjects who visited Yeungnam University Respiratory Center from January 2012 to December 2013. RESULTS: Of the 11,672 specimens undergoing AFB culture, 1,310 specimens (11.2%) showed positive results. Of these specimens, NTM was recovered from 587 specimens, showing a recovery rate of 44.8%. Identification test for NTM was performed on 191 subjects; the results were as follows: M. avium-intracellulare complex (MAC) 123 (64.4%), M. abscessus 20 (10.5%), M. kansasii 12 (6.3%), and 33 other NTM germ strains. Of the 382 subjects with NTM, 167 were diagnosed with pulmonary NTM disease (43.7%), however virulence differed depending on NTM strain. Multivariate analysis showed that nodular bronchiectasis, the nodules, and finding consistent with cavity under imaging study were statistically significant for triggering pulmonary NTM disease. AFB culture showing MAC and M. abscessus was statistically significant as well. Positive predictive value for NTM polymerase chain reaction (NTM-PCR) was 88.6%. CONCLUSION: Results for NTM recovery rate within the Daegu area were similar to those for the Seoul metropolitan area. We can assume that NTM infection is increasing in our community, therefore AFB-positive subjects (1) should undergo NTM-PCR, (2) should have their culture results checked for differentiation of mycobacterium tuberculosis complex (MTB) from NTM, and (3) undergo NTM identification test to confirm its type. Administration of treatment with the above results should be helpful in improving the patients' prognosis.
Citations
Citations to this article as recorded by
Distribution and Antimicrobial Resistance of Non-Tuberculous Mycobacteria during 2015∼2020: A Single-Center Study in Incheon, South Korea Jiwoo Kim, Hyo-Jin Ju, Jehyun Koo, Hyeyoung Lee, Hyeonhwan Park, Kyungcheol Song, Jayoung Kim The Korean Journal of Clinical Laboratory Science.2021; 53(3): 225. CrossRef
Study on the Prevalence of Lung Disease of Non-Tuberculosis Mycobacterium Isolated from Respiratory Specimens in Gwangju Second Hospital over the Last 10 Years Hae-Gyeong Baek The Korean Journal of Clinical Laboratory Science.2020; 52(4): 349. CrossRef
Recovery Rates of Non-Tuberculous Mycobacteria from Clinical Specimens Are Increasing in Korean Tertiary-Care Hospitals Namhee Kim, Jongyoun Yi, Chulhun L. Chang Journal of Korean Medical Science.2017; 32(8): 1263. CrossRef
Dong Gun Kim, Min Kyoung Kim, Sung Hwa Bae, Sung Ae Koh, Sung Woo Park, Hyun Je Kim, Myung Jin Kim, Hyo Jin Jang, Kyung Hee Lee, Kwan Ho Lee, Jin Hong Chung, Kyung Chul Shin, Hun Mo Ryoo, Myung Soo Hyun
Yeungnam Univ J Med. 2011;28(1):31-44. Published online June 30, 2011
BACKGROUND The optimal timing of treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKI) in NSCLC patients has not yet been determined. METHODS: We separated 228 patients with advanced/metastatic NSCLC treated with gefitinib into an early gefitinib group (patients who received gefitinib as first- or second-line treatment) and a delayed gefitinib group (patients who received gefitinib as third or fourth-line treatment) and attempted to determine whether the timing of gefitinib treatment affected clinical outcomes. RESULTS: Median overall survival (OS), progression free survival (PFS), and median OS from first-line treatment of advanced/metastatic disease (OSt) for 111 patients in the early gefitinib group were 6.2 months, 3.3 months, and 11.6 months. However, median OS, PFS, and OSt for 84 patients in the delayed gefitinib group were 7.8 months, 2.3 months, and 22.7 months. No differences in OS and PFS were observed between the 2 groups. However, OSt was significantly longer in the delayed gefitnib group. Timing of gefitinib therapy was one of the independent predictors of OSt. Hb > or = 10 g/dl, and having never smoked, and ECOG performance status < or =1 were independent predictors of better PFS. CONCLUSION: Deferral of gefitinib therapy in patients with advanced or metastatic NSCLC may be preferable if they are able to tolerate chemotherapy.
A paragonimiasis infestation is caused by the paragonimus species. Paragonimiasis mainly occurs by ingestion of raw or undercooked freshwater crabs or crayfish. In our country, the prevalence of paragonimiasis was high until late 1960s due to eating habits, but after the 1970s the prevalence of the disease has markedly decreased and now the disease is rarely seen. The diagnosis of tuberculosis by Chest X-ray is often confused with pulmonary carcinoma, bacillary and parasitic infections, and chronic mycosis. Pulmonary paragonimiasis must be considered in the differential diagnosis of lung cancer especially in the appropriate clinical setting because effective treatment with praziquantel can be rewarding. We report a case of a 58-year-old woman with pulmonary paragonimiasis that was suspicious for lung cancer, as detected by biopsy.
Citations
Citations to this article as recorded by
A Case of Delayed Diagnosis of Pulmonary Paragonimiasis due to Improvement after Anti-tuberculosis Therapy Suhyeon Lee, Yeonsil Yu, Jinyoung An, Jeongmin Lee, Jin-Sung Son, Young Kyung Lee, Sookhee Song, Hyeok Kim, Suhyun Kim Tuberculosis and Respiratory Diseases.2014; 77(4): 178. CrossRef
Lymphangioleiomyomatosis (LAM) is a rare, cystic lung disease that is associated with mutation in the tuberous sclerosis genes, renal angiomyolipomas, lymphatic spread and a remarkable female gender predilection. The pathology of LAM is represented by the proliferation of immature smooth muscle cells in the walls of airways, and venules and lymphatic vessels in the lung. The clinical course of LAM is characterized by progressive dyspnea on exertion, recurrent pneumothorax and collections of chylous fluid. The diagnosis of pulmonary LAM can be made on chest X-ray, a high-resolution CT scan and lung biopsy. We experienced a case of pulmonary lymphangioleiomyomatosis in a 28-years-old female patient who had suffered from progressive dyspnea on exertion, so we report on it along with a brief review of the relevant literature.
Pulmonary alveolar proteinosis (PAP) is a rare disorder that's characterized by accumulation of surfactant components in the alveolar space. Idiopathic PAP is recognized as an autoimmune disease that's due to impaired alveolar macrophage function and this caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF). We report here a case of pulmonary alveolar proteinosis that was deemed interstitial lung disease at the initial diagnosis. A 61-year-old man presented with intermittent blood tinged sputum and dyspnea on exertion. The man was a painter for 30 years and he had a 10 pack-years smoking history. Chest computerized tomography (CT) revealed multifocal ground-glass opacity with interstitial thickening at both lungs. His pulmonary function tests and methacholine test revealed non specific results. He was diagnosed with interstitial lung disease on the basis of the chest CT finding and occupational history. However, seven months later, his symptoms progressed. Follow-up chest CT was performed. Wedge resection via video-assisted thoracoscopic surgery (the anterior basal segment of the left lower lobe) was done. Microscopic examination showed large groups of alveoli with excessive amounts of surfactant and a complex mixture of protein and lipid (fat) molecules. Finally, he was diagnosed as having pulmonary alveolar proteinosis.
Citations
Citations to this article as recorded by
Pulmonary alveolar proteinosis in a 15-year-old girl Yechan Kyung, Jihyun Kim, Hong Kwan Kim, Joungho Han, Kangmo Ahn Allergy, Asthma & Respiratory Disease.2015; 3(1): 86. CrossRef
Eosinophilic myositis is a rare idiopathic inflammatory muscle disease, and the patients with this malady present with diverse signs and symptoms such as muscle swelling, tenderness, pain, weakness, cutaneous lesions and eosinophilia. The etiology and pathogenesis of eosinophilic myositis remain elusive. Several drugs may occasionally initiate an immune mediated inflammatory myopathy, including eosinophilic myositis. We report here on a case a 17-year-old female patient who had taken anti-tuberculosis medicine for tuberculosis pleurisy. She presented with many clinical manifestations, including fever, skin rash, proximal muscle weakness, dyspnea, dysphagia and hypereosinophilia. She was diagnosed with eosinophilic myositis by the pathologic study. The muscle weakness progressed despite of stopping the anti-tuberculosis medicine, but the myositis promptly improved following the administration of glucocorticoid. Although drug induced myopathies may be uncommon, if a patient presents with muscular symptoms, then physicians have to consider the possibility of drug induced myopathies.
Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects the medium-sized muscular arteries, with occasional involvement of the small muscular arteries. As with other vasculitides, PAN can affect any organ system, including the cardiovascular, gastrointestinal and central nervous systems. The prognosis for patients with untreated PAN is relatively poor, with five-year survival rates of approximately 13 percent. The outcome has improved with proper therapy to approximately 80 percent survival at five years. We report here on a case of a 46 year old man with polyarteritis nodosa and who suffered from pulmonary tuberculosis.
BACKGROUND Malignant pulmonary nodules account for 30 to 40 percent of all solitary pulmonary nodules (SPNs). Therefore, characterization of SPNs is very important for treatment. Recently, dynamic CT has been widely used for tissue characterization and formation of differential diagnoses. The purpose of this study was to evaluate the ability of dynamic CT to formulate the differential diagnosis of SPNs. MATERIALS AND METHODS: Nineteen patients with SPNs underwent dynamic CT (unenhanced scans, followed by a series of images at 20, 40, 60, 80, 100, 120, 140, 160, and 180 sec after intravenous injection of contrast medium). Diagnosis of SPN was performed based on pathologic findings in needle biopsy samples. Peak enhancement, net enhancement, slope of enhancement, and maximum relative enhancement ratio of the SPN were measured on dynamic CT, and Levene's test was performed to assess benignancy and malignancy. RESULTS: Twelve SPNs were confirmed to have malignant pathology. There were no significant differences between benign and malignant nodules with respect to peak enhancement (p=0.787), net enhancement (p=0.135), or slope of enhancement (p=0.698). The maximal enhancement ratio was increased in malignancy compared to benignancy, but the difference was not statistically significant (p=0.094). CONCLUSION: In our study, the hemodynamic characteristics of dynamic CT were not significantly different between benign and malignant nodules. Therefore, long-term studies of larger patient samples are required to confirm our findings.
Pulmonary hypertension is an increase in blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries. Depending on the cause, pulmonary hypertension can be a severe disease with markedly decreased exercise tolerance and right-sided heart failure. Pulmonary hypertension can present as one of five different types: arterial, venous, hypoxic, thromboembolic, or miscellaneous. Chronic obstructive pulmonary disease with severe pulmonary hypertension is a rare disease. A 52-year-old man presented with a complaint of aggravating dyspnea. The mean pulmonary arterial pressure was 61.5 mmHg by Doppler echocardiogram. The patient was prescribed diuretics, digoxin, bronchodilator, sildenafil, bosentan and an oxygen supply. However, he ultimately died of cor pulmonale. Thus, diagnosis and early combination therapy are important.
Varicella is a contagious infection in childhood disease typically affecting children aged 2-8 years and usually follows benign outcome. In the adult, clinical presentation is more severe and more commonly associated with complications. Varicella pneumonia, although rare, is a potentially life-threatening complication that should be suspected in any adult with varicella and respiratory symptoms. We report a case of varicella pneumonia in immunocompetent patient. The characteristic radiographic findings consisted of diffuse scattered coarse nodular infiltrations, less than 1cm sized, with ground glass opacity and consolidation in both lung fields. The patients was started on intravenous acyclovir. The chest radiograph performed 2 weeks later showed complete resolution of the pulmonary lesions.
Background :Interleukin-1 (IL-1) and neutrophil appear to contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). Reactive oxygen species, as well as elastase released from activated neutrophil, are thought to play pivotal roles in the experimental models of acute lung leak. This study investigated whether aerosolized vitamin E can attenuate acute lung injury induced by IL-1 in rats.
Materials and Methods:We intratracheally instilled either saline or IL-1 with and without pretreatment with aerosolized vitamin E in rats. After 5 hours of intratracheal instillation, lung lavage neutrophils, lung lavage protein concentration, lung myeloperoxidase(MPO) activity and lung wet weight to dry weight ratio(WW/DW) were measured in rat.
Results :In rats given IL-1 intratracheally, lung lavage neutrophils, lung lavage protein concentration, lung MPO activity and WW/DW were higher. Pretreatment with aerosolized vitamin E decreased lung lavage neutrophils, lung MPO activity and WW/DW in rats given IL-1 intratracheally.
Conclusion :These results suggest that direct pulmonary supplement of vitamin E decreases lung inflammation and leak in rats given IL-1 intratracheally.
The tumor lysis syndrome has been described as biochemical disturbances associated with rapid destruction of tumor cells and subsequent synchronized massive release of cellular breakdown products sufficient to overwhelm excretory mechanisms and the body's normal reutilization capacity. The cardinal signs of the tumor lysis syndrome are hyperkalemia, hyperphosphatemia, hypocalcemia and hyperuricemia. Gefitinib (Iressa) is an oral, selective epidermal growth factor receptor (EGFR) inhibitor that has activity in female, non-smoker and non-small cell lung cancer with an EGFR mutation. Gefitinib is a well tolerated drug with few side effects. It has been associated with skin rash, diarrhea, nausea, a decrease in liver function and interstitial lung disease. However, there is no prior report of the tumor lysis syndrome associated with gefitinib. We report a case of a 54 year-old woman who developed tumor lysis syndrome that might have been induced by gefitinib after the treatment of adenocarcinoma of lung with an EGFR mutation.
BACKGROUND Malignant pulmonary nodules account for about 30 to 40 percent of solitary pulmonary nodules (SPN). Therefore, tissue characterization of SPNs is very important. Recently, PET/CT has been widely used for tissue characterization, and has become of importance. The purpose of this study was to compare and to assess multiple factors in PET/CT comparing benign and malignant nodules. MATERIALS AND METHOD: Nineteen patients with SPN underwent PET/CT and biopsy. The difference of standardized uptake value 1 (SUV1), standardized uptake value 2 (SUV2) and retention index in PET/CT between malignancy and benignancy were compared by Levene's test. RESULT: There were twelve malignant and seven benign nodules. SUV1 and SUV2 were significantly different between malignant nodule and benign nodule (p=0.006 and 0.022), but retention index was not significantly different between malignant nodule and benign nodule (p=0.526). By receiver-operating-characteristic (ROC) analysis, the sensitivity was 66.7% and the specificity was 71.4% at a cut off value of 5.40 in SUV1. The sensitivity was 75% and the specificity was 71.4% at cut off value of 7.45 in SUV2. CONCLUSION: There was a statistically significant difference in SUV1 and SUV2 between benign and malignant nodules. However, the cut off value of SUV1 and SUV2 by receiver-operating-characteristic (ROC) analysis was 5.40 and 7.45 which is different from previous studies. Therefore, studies on a larger sample of patients are required for confirmation.